Replies to post #804297 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Very good to get to see/read the Q&A portion. Wish they would release data on the information arm that Liau thinks there are about a dozen survivors

It would be very interesting to see the rapid progression results as that was randomized w/o cross-over and OS as the efficacy outcome. I am guessing that it was not good else they would have disclosed it.

They also could provide OS from the main trial comparing non-crossovers from both arms (yes, the treatment arm also had a crossover option that would allow them to stay on -L). That would be unbiased and not confounded by crossover.

So 3 sources of randomized OS data and NWBO fails to disclose any.

BTW, LL also noted they had results in from the earlier trials that was consistent with the P3. So they knew by 2011 that PFS was doomed to fail, but they saved time and money by repurposing the doomed trial instead of a design that incorporated what they had already learned.